Home >

Welcome to ASCO Connection Discussion

LOGIN TO START A DISCUSSION
Molecular Oncology Tumor Board
ASCO University
May 11, 2016 9:46 AM
Read more to answer the following questions: 1) Would further imaging be required before discussing a plan for systemic therapy?  2) Which of the available tissue specimen/sites would be appropriate for HER2 testing: tissue from the primary resection specimen, metastasis from the para-aortic lymph...
International
ASCO International Affairs
May 09, 2016 11:24 AM
ASCO partnered with local organizers to hold two Cancer Control in Primary Care (CCPC) courses in November 2015 and February 2016. The evaluation results for both courses indicate that the majority of respondents intend to make practice changes and gained new knowledge and skills as a result of...
Practice
Mark R. Hutchins, MD
Apr 26, 2016 10:50 PM
 
Has there ever been a PRCT of AC/T vs "other" in a pure TNBC stratified group (in the NeoAdj setting or the Adj setting?) showing that AC/T vs "other" showed a superior survival? When we say that AC/T shows a survival advantage, advantage over what?
The origninal AC vs CMF showed little if any...
Molecular Oncology Tumor Board
ASCO University
Apr 13, 2016 9:33 AM
Read more to answer the following questions: 1) What are available second line therapy options? 2)  Do you test for PD-L1 prior to recommending therapy? 3) Does smoking history affect your treatment recommendations?
Molecular Oncology Tumor Board
ASCO University
Mar 09, 2016 9:36 AM
Read more to answer the following questions: 1) What molecular testing on tissue should be performed in newly diagnosed DLBCL? 2) How need for molecular testing affects tissue requirements and biopsy size? 3) What staging studies and serum biomarkers would you obtain?  

Pages

Tweets from ASCO

Tweets from Oncology Community